A61K 9/5042
Cellulose
Official title: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
A61K9/5042 (Cellulose) appears on 1,317 US grants and 2,096 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,317
- Published applications
- 2,096
- Assignees
- 816
- Inventors
- 3,187
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 4 | 0 |
| 1978 | 3 | 0 |
| 1979 | 3 | 0 |
| 1980 | 8 | 0 |
| 1981 | 1 | 0 |
| 1982 | 4 | 0 |
| 1983 | 6 | 0 |
| 1984 | 5 | 0 |
| 1985 | 5 | 0 |
| 1986 | 3 | 0 |
| 1987 | 5 | 0 |
| 1988 | 7 | 0 |
| 1989 | 21 | 0 |
| 1990 | 16 | 0 |
| 1991 | 13 | 0 |
| 1992 | 15 | 0 |
| 1993 | 15 | 0 |
| 1994 | 16 | 0 |
| 1995 | 16 | 0 |
| 1996 | 15 | 0 |
| 1997 | 17 | 0 |
| 1998 | 20 | 0 |
| 1999 | 18 | 0 |
| 2000 | 10 | 0 |
| 2001 | 21 | 9 |
| 2002 | 21 | 29 |
| 2003 | 32 | 52 |
| 2004 | 23 | 51 |
| 2005 | 10 | 50 |
| 2006 | 16 | 68 |
| 2007 | 10 | 81 |
| 2008 | 6 | 73 |
| 2009 | 8 | 75 |
| 2010 | 17 | 80 |
| 2011 | 18 | 83 |
| 2012 | 30 | 57 |
| 2013 | 40 | 86 |
| 2014 | 71 | 138 |
| 2015 | 71 | 143 |
| 2016 | 71 | 157 |
| 2017 | 76 | 128 |
| 2018 | 76 | 102 |
| 2019 | 72 | 109 |
| 2020 | 74 | 95 |
| 2021 | 73 | 97 |
| 2022 | 51 | 72 |
| 2023 | 49 | 65 |
| 2024 | 64 | 94 |
| 2025 | 47 | 62 |
| 2026 | 21 | 40 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Prolonged-release pharmaceutical composition for oral administration of sultiame6 Oct 2026US 12,751,928 B2Advicenne
- Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics8 Sep 2026US 12,728,110 B2Flamel Ireland Limited
- Delayed-release formulation of duloxetine1 Sep 2026US 12,721,817 B1Almatica Pharma LLC
- Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof28 Jul 2026US 12,691,074 B2Impax Laboratories, LLC
- Alkaline phosphatase formulations and uses thereof28 Jul 2026US 12,691,077 B2Theriva Biologics, Inc.
- Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof1 Oct 2026US 2026/0294817 A1Impax Laboratories, LLC
- Enriched Withania somnifera Based Dietary Composition and a Method Thereof24 Sep 2026US 2026/0284137 A1Arjuna Natural Private Limited
- Oral pharmaceutical compositions of dabigatran etexilate17 Sep 2026US 2026/0272904 A1Breckenridge Pharmaceutical, Inc.
- Inhalable Serotonin Receptor Agonist Formulations20 Aug 2026US 2026/0240763 A1Pinata Holdings Inc.
- Pharmaceutical formulations comprising naltrexone and/or bupropion13 Aug 2026US 2026/0232599 A1Nalpropion Pharmaceuticals LLC
Most cited
By later US patents
- Orally administrable opioid formulations having extended duration of effect437US 5,968,551 APurdue Pharma L. P. · 1999
- Delivery of multiple doses of medications377US 5,837,284 A1998
- Opioid formulations having extended controlled released306US 5,958,459 APurdue Pharma L. P. · 1999
- Sustained release pharmaceutical composition300US 5,378,474 AF. H. Faulding & Co. Limited · 1995
- Sustained release pharmaceutical composition296US 5,202,128 AF. H. Faulding & Co. Limited · 1993